Esperion Therapeutics (ESPR)
(Delayed Data from NSDQ)
$1.92 USD
+0.30 (18.52%)
Updated Aug 6, 2025 04:00 PM ET
After-Market: $1.91 -0.01 (-0.52%) 7:58 PM ET
3-Hold of 5 3
C Value A Growth F Momentum C VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
ESPR 1.92 +0.30(18.52%)
Will ESPR be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for ESPR based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ESPR
ESPR's Q2 Earnings & Revenues Trump Estimates, Stock Rises
Esperion Therapeutics (ESPR) Reports Q2 Loss, Tops Revenue Estimates
ESPR: What are Zacks experts saying now?
Zacks Private Portfolio Services
Earnings Preview: Crinetics Pharmaceuticals, Inc. (CRNX) Q2 Earnings Expected to Decline
Neurocrine Biosciences (NBIX) Q2 Earnings and Revenues Beat Estimates
Analysts Estimate Esperion Therapeutics (ESPR) to Report a Decline in Earnings: What to Look Out for
Other News for ESPR
Esperion Therapeutics Inc (ESPR) Q2 2025 Earnings Call Highlights: Strong US Net Product ...
Esperion Therapeutics (ESPR) Sees Revenue Surge, Eyes Profitability by 2026
Q2 2025 Esperion Therapeutics Inc Earnings Call Transcript
Esperion rises after revenue beat, Q1 profitability expectation
Esperion expects sustainable profitability in Q1 2026 as double-digit growth continues